Aurinia Pharmaceuticals Inc.

DB:IKAP Stock Report

Market Cap: €1.2b

Aurinia Pharmaceuticals Future Growth

Future criteria checks 4/6

Aurinia Pharmaceuticals is forecast to grow earnings and revenue by 52.4% and 17.3% per annum respectively while EPS is expected to grow by 52.3% per annum.

Key information

52.4%

Earnings growth rate

52.3%

EPS growth rate

Biotechs earnings growth42.3%
Revenue growth rate17.3%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:IKAP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263451291031857
12/31/202527986741077
12/31/20242365-5137
9/30/2024220-232829N/A
6/30/2024207-50-2-2N/A
3/31/2024191-63-21-20N/A
12/31/2023176-78-34-33N/A
9/30/2023159-77-38-37N/A
6/30/2023160-73-40-39N/A
3/31/2023147-97-65-64N/A
12/31/2022134-108-80-80N/A
9/30/2022129-115-110-116N/A
6/30/202288-157-141-141N/A
3/31/202266-168-151-151N/A
12/31/202146-181-159-158N/A
9/30/202172-156-138-129N/A
6/30/202158-148-125-117N/A
3/31/202151-127-109-101N/A
12/31/202050-103-77-70N/A
9/30/20200-129-104-98N/A
6/30/20200-110-83-82N/A
3/31/20200-102-73-73N/A
12/31/20190-88-64-64N/A
9/30/20190-57-52-52N/A
6/30/20190-52-51-51N/A
3/31/20190-61-50-50N/A
12/31/20180-53-52-52N/A
9/30/20180-53-47-47N/A
6/30/20180-48N/A-44N/A
3/31/20180-34N/A-46N/A
12/31/20170-71N/A-41N/A
9/30/20170-76N/A-36N/A
6/30/20170-70N/A-32N/A
3/31/20170-71N/A-23N/A
12/31/20160-23N/A-19N/A
9/30/20160-19N/A-19N/A
6/30/20160-17N/A-20N/A
3/31/20160-14N/A-19N/A
12/31/20150-19N/A-18N/A
9/30/20150-21N/A-16N/A
6/30/20150-13N/A-15N/A
3/31/20150-23N/A-16N/A
12/31/20140-19N/A-17N/A
9/30/20141-15N/A-16N/A
6/30/20141-17N/A-14N/A
3/31/20141-7N/A-10N/A
12/31/20131-3N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IKAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: IKAP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IKAP is expected to become profitable in the next 3 years.

Revenue vs Market: IKAP's revenue (17.3% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: IKAP's revenue (17.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IKAP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurinia Pharmaceuticals Inc. is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Dae Gon HaBTIG
Neil MaruokaCanaccord Genuity